PMID- 28902534
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20181202
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 32
DP  - 2017 Nov 10
TI  - Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib 
      (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients 
      With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
PG  - 3662-3670
LID - 10.1200/JCO.2017.72.7297 [doi]
AB  - Purpose This phase III, randomized, placebo-controlled, double-blind study 
      determined whether motesanib improved progression-free survival (PFS) compared 
      with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian 
      patients with stage IV/recurrent nonsquamous non-small-cell lung cancer. Patients 
      and Methods Patients were randomly assigned (1:1) to receive oral motesanib 125 
      mg or placebo once daily plus paclitaxel 200 mg/m(2) IV and carboplatin area 
      under the concentration-time curve 6 mg/mL ⋅ min IV for up to six 3-week cycles. 
      Random assignment was stratified by epidermal growth factor receptor status, 
      region, and weight loss in the 6 months before assignment. The primary end point 
      was PFS, the key secondary end point was overall survival, and other secondary 
      end points were objective response rate, time to tumor response, duration of 
      response, and adverse events (AEs). Results Four hundred one patients were 
      assigned to receive motesanib plus P/C (n = 197) or placebo plus P/C (n = 204). 
      Median PFS was 6.1 v 5.6 months for motesanib versus placebo (stratified log-rank 
      test P = .0825; stratified hazard ratio, 0.81; 95% CI, 0.64 to 1.03; P = .0820); 
      median overall survival was not reached versus 21.6 months ( P = .5514). In 
      secondary analyses, the objective response rate was 60.1% v 41.6% ( P < .001); 
      median time to tumor response, 1.4 v 1.6 months, and median duration of response, 
      5.3 v 4.1 months. Incidence of grade >/= 3 AEs (86.7% v 67.6%) and AEs that led to 
      drug discontinuation (32.7% v 14.2%) were higher with motesanib than with 
      placebo. AEs reported more frequently with motesanib were GI disorders, 
      hypertension, and gallbladder related. Conclusion Motesanib plus P/C did not 
      significantly improve PFS versus placebo plus P/C in East Asian patients with 
      stage IV/recurrent nonsquamous non-small-cell lung cancer.
FAU - Kubota, Kaoru
AU  - Kubota K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Yoshioka, Hiroshige
AU  - Yoshioka H
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Oshita, Fumihiro
AU  - Oshita F
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Hida, Toyoaki
AU  - Hida T
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Yoh, Kiyotaka
AU  - Yoh K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Hayashi, Hidetoshi
AU  - Hayashi H
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Kato, Terufumi
AU  - Kato T
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Kaneda, Hiroyasu
AU  - Kaneda H
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Yamada, Kazuhiko
AU  - Yamada K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Tanaka, Hiroshi
AU  - Tanaka H
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Ichinose, Yukito
AU  - Ichinose Y
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Park, Keunchil
AU  - Park K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Cho, Eun Kyung
AU  - Cho EK
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Lee, Kyung-Hee
AU  - Lee KH
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Lin, Chih-Bin
AU  - Lin CB
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Yang, James Chih-Hsin
AU  - Yang JC
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Hara, Kaori
AU  - Hara K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Asato, Takayuki
AU  - Asato T
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
FAU - Nakagawa, Kazuhiko
AU  - Nakagawa K
AD  - Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda 
      Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; 
      Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki 
      Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center 
      Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, 
      Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal 
      Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, 
      Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, 
      National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center 
      Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, 
      Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, 
      Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; 
      James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan 
      University Cancer Center, Taipei City, Peoples Republic of China.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170913
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Indoles)
RN  - 0 (Oligonucleotides)
RN  - 25X51I8RD4 (Niacinamide)
RN  - BG3F62OND5 (Carboplatin)
RN  - F60NE4XB53 (imetelstat)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
CIN - J Thorac Dis. 2018 Feb;10 (2):617-620. PMID: 29607123
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/*administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*ethnology/pathology
MH  - Double-Blind Method
MH  - Female
MH  - Hong Kong
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Japan
MH  - Lung Neoplasms/*drug therapy/*ethnology/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Neoplasm Staging
MH  - Niacinamide/administration & dosage/*analogs & derivatives
MH  - Oligonucleotides
MH  - Paclitaxel/*administration & dosage
MH  - Republic of Korea
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2017/09/14 06:00
MHDA- 2017/11/14 06:00
CRDT- 2017/09/14 06:00
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2017/09/14 06:00 [entrez]
AID - 10.1200/JCO.2017.72.7297 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 Nov 10;35(32):3662-3670. doi: 10.1200/JCO.2017.72.7297. Epub 
      2017 Sep 13.